HealthLower ESCO2 Raises PARP Inhibitor Sensitivity in Cancer Cell ModelsBy Naomi CalderNov 5, 2026, 8:56 PM UTC
HealthAimedBio Reports First Patient Dosed in Boehringer Ingelheim Phase I TrialBy Naomi CalderNov 3, 2026, 2:57 AM UTC
BusinessActinium Names Maenpaa to Lead Licensing and Partnership StrategyBy Helena WardOct 16, 2026, 6:34 PM UTC
HealthElephas elive Platform Classified Clinical Outcomes for 26 of 28 PatientsBy Naomi CalderOct 15, 2026, 10:12 PM UTC
